Introduction: The incidence of thyroid cancer (TC) has been increasing globally, yet the proper identification of malignant tumors remains challenging. Copy number alterations (CNAs) are common genomic events in cancer and play a significant role in identifying relevant markers and classifying tumor types, contributing to the understanding of the genetic mechanisms underlying cancer, since the analysis of genes present in these regions helps in the evaluation of the genomic profile, in addition to providing potential biomarkers. Objectives: identify patterns in CNAs of neoplastic thyroid tissue samples. Methods: The study was approved by the ethics committee IEC/SVS/MS (ID 3.317.960), involved 38 patients with TC admitted to the Ophyr Loyola Hospital in the state of Pará, Brazil. Samples corresponded to 7 benign and 31 malignant tumors, from 34 female and 4 male patients. Tumor sample DNA was extracted and integrity number (DIN) >7. CNAs were detected by aCGH, using Aberration Detection Method 2 (ADM-2) algorithm. Log?Ratio >0.25 and p ? 0.05 were considered significant. Results: CNAs were more frequent in malignant tumors and in female patient samples. The chromosomal region 14q32.33 was frequently in benignant and malignant tumors, the chromosomal region 14q11.2 was frequently altered malignant tumors. Non-coding RNA (ncRNA) genes are prominent in terms of the frequency in tumor samples. Genes frequently altered in malignant tumors of female and male patients were associated with different biological processes, highlighting the possible sex bias of TC. CNAs can interfere in a complex manner in the modulation of the tumor microenvironment in TC. Conclusion: the results suggest that age, sex and altered chromosomal regions are associated with tumor types. Our results reinforce the role of CNAs in the progression of TC and highlight the importance of clinical and CNAs data for the classification of thyroid tumors, contributing to new approaches for classification, diagnosis and treatment of this neoplasm. Although the incidence of thyroid cancer (TC) has been increasing globally, the proper identification of malignant tumors remains challenging. CNAs play an important role in the identification of relevant markers and in the classification of tumor types.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
